Abstract:Brucellosis is a worldwide distributed zoonosis caused by members of the genus Brucella. One of them, Brucella abortus, is the etiological agent of bovine brucellosis. With the attenuated strain B. abortus S19 a vaccine is available. However, both, virulence (safety) and the ability to induce a protective B and T cell response (efficacy) have to be tested in suitable assays before successful use in the field. For this purpose, several macrophage cell lines of various origins have been used while splenic macrophages are the preferred host cells in vivo. We here characterized the in vitro response of the murine splenic macrophage cell line CRL 2471(I-13.35) to B. abortus. This cell line still depends on the presence of colony-stimulating factor 1 (CSF1) and is derived from LPS resistant (TLR4 deficient) C3H/HeJ mice. For infection the vaccine strain B. abortus S19A as well as the formerly described isogenic deletion mutant B. abortus S19A ΔmglA 3.14 were used. While numbers of viable bacteria did not differ significantly between the vaccine strain and the deletion mutant at 6h post infection, a higher bacterial load was measured in case of the mutant at 24h and 48h after infection. This was also true, when IFNγ was used for macrophage activation. A comprehensive gene expression profile of macrophages was analysed 6 and 24h after infection by means of an RT-PCR based gene expression array. The mutant strain B. abortus S19A ΔmglA 3.14 elicited a stronger cellular response of the splenic macrophages as compared to the parental vaccine strain. This was most prominent for the pro-inflammatory cytokines IL-1α, IL-1β, TNF-α and IL6 as well as for the chemokine ligands CXCL1, CXCL2, CXCL10, CCL2, CCL5, CCL7, CCL17 and the co-stimulatory molecules CD40 and ICAM1. While these differences were also present in IFNγ-stimulated macrophages, an addition of IFNγ after infection not only resulted in a dramatic increase of the translation of the afore mentioned genes but also resulted in the translation of IFNß1, IL12ß, MIP1α and β (CCL3, CCL4), NOS2 (and SOD2) and FAS. Conclusion: The TLR4 deficient murine splenic macrophage cell line CRL 2471 was used for the first time for the characterization of macrophage-Brucella interaction to investigate the pre-immune phase of brucellosis in vitro. Typical pro-inflammatory cytokines and certain surface receptors were differentially induced by B. abortus S19 A and an isogenic ΔmglA deletion mutant in vitro. This model may be useful for further studies to characterize the inflammatory response of splenic macrophages to intracellular gram-negative bacteria avoiding cell responses to soluble LPS.

Characterization of Brucella abortus S19 as a challenge strain for use in a mouse model of brucellosis

[Construction of Brucella Abortus A19-delta VirB12 Mutant and Evaluation of Its Protective Efficacy Against 2308 Strain Challenge in BALB/c Mice].

Intratracheal inoculation results in Brucella-associated reproductive disease in male mouse and guinea pig models of infection

Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice

Characterization of Brucella Abortus Mutant Strain Δ22915, a Potential Vaccine Candidate

A study on the use of male animal models for developing a live vaccine for brucellosis

Immunization With a Combination of Four Recombinant Brucella abortus Proteins Omp16, Omp19, Omp28, and L7/L12 Induces T Helper 1 Immune Response Against Virulent B. abortus 544 Infection in BALB/c Mice

The Brucella Melitensis M5-90ΔmanB Live Vaccine Candidate is Safer Than M5-90 and Confers Protection Against Wild-Type Challenge in BALB/c Mice.

Brucella melitensis 16MΔhfq attenuation confers protection against wild-type challenge in BALB/c mice.

Protective efficacy by various doses of a new brucellosis vaccine candidate based on Salmonella strains expressing Brucella abortus BSCP31, Omp3b and superoxide dismutase against brucellosis in murine model

Evaluation of real-time PCR as an alternative for potency testing of Brucella abortus vaccines

Parenteral Vaccination with a Live Brucella melitensis Mutant Protects against Wild-Type B. melitensis 16M Challenge

A novel Galleria mellonella experimental model for zoonotic pathogen Brucella

An Alternative Test Procedure for the Protective Efficacy of Brucella Vaccines

Ag85A, As an S2 Vaccine Carrier, Reduces the Toxicity of the S2 Vaccine and Enhances the Protective Ability of Mice against Brucella

In Situ Characterization of Splenic Brucella Melitensis Reservoir Cells During the Chronic Phase of Infection in Susceptible Mice.

Inflammatory response of TLR4 deficient spleen macrophages (CRL 2471) to Brucella abortus S19 and an isogenic ΔmglA deletion mutant

Contrasting roles for IgM and B-cell MHCII expression in Brucella abortus S19 vaccine-mediated efficacy against B. melitensis infection

Evaluation of the Efficacy of the Brucella canis RM6/66 Δ vjbR Vaccine Candidate for Protection against B. canis Infection in Mice

Brucella neotomae Recapitulates Attributes of Zoonotic Human Disease in a Murine Infection Model

A Brucella Omp16 Conditional Deletion Strain Is Attenuated in BALB/c Mice